See more : DHB Capital Corp. (DHBCU) Income Statement Analysis – Financial Results
Complete financial analysis of Bioxytran, Inc. (BIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bioxytran, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Redwood Scientific Technologies, Inc. (RSCI) Income Statement Analysis – Financial Results
- Juniper Hotels Limited (JUNIPER.NS) Income Statement Analysis – Financial Results
- Advanced Fiber Resources (Zhuhai), Ltd. (300620.SZ) Income Statement Analysis – Financial Results
- Gallantt Ispat Limited (GALLANTT.NS) Income Statement Analysis – Financial Results
- Beauce Gold Fields Inc. (BGFGF) Income Statement Analysis – Financial Results
Bioxytran, Inc. (BIXT)
About Bioxytran, Inc.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.08K | 246.50K | 255.82K | 275.62K | 417.34K | 312.90K | 76.30K | 16.13K | 0.00 | 0.00 |
| Cost of Revenue | 8.29K | 3.64K | 0.00 | 0.00 | 0.00 | 0.00 | 103.98K | 96.30K | 135.69K | 165.98K | 197.39K | 121.92K | 19.07K | 4.03K | 0.00 | 0.00 |
| Gross Profit | -8.29K | -3.64K | 0.00 | 0.00 | 0.00 | 0.00 | 87.10K | 150.19K | 120.14K | 109.64K | 219.95K | 190.98K | 57.22K | 12.10K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.58% | 60.93% | 46.96% | 39.78% | 52.70% | 61.04% | 75.00% | 74.99% | 0.00% | 0.00% |
| Research & Development | 1.15M | 977.77K | 2.01M | 544.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.47M | 1.16M | 2.20M | 724.18K | 1.63M | 214.71K | 397.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 197.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.67M | 1.16M | 2.20M | 724.18K | 1.63M | 214.71K | 397.69K | 821.47K | 2.21M | 1.39M | 2.19M | 2.48M | 2.41M | 341.13K | 272.15K | 24.22K |
| Other Expenses | 0.00 | 3.64K | 582.86K | 247.87M | 1.12B | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | -348.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Operating Expenses | 3.82M | 2.14M | 4.21M | 1.27M | 1.63M | 214.71K | 397.69K | 821.47K | 2.21M | 1.39M | 2.19M | 2.48M | 2.41M | 341.13K | 272.15K | 24.22K |
| Cost & Expenses | 3.82M | 2.14M | 4.21M | 1.27M | 1.63M | 214.71K | 501.66K | 917.77K | 2.35M | 1.56M | 2.39M | 2.60M | 2.43M | 345.17K | 272.15K | 24.22K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.05K | 925.00 | 919.00 | 0.00 |
| Interest Expense | 541.83K | 519.55K | 313.61K | 1.27M | 227.01K | 8.38K | 7.80K | 7.80K | 7.80K | 7.80K | 12.66K | 3.55K | 4.40K | 8.36K | 5.12K | 109.00 |
| Depreciation & Amortization | 8.29K | 3.64K | 4.21M | 1.27M | 1.63M | 215.11K | 17.54K | 27.63K | 54.78K | 58.19K | 51.06K | 40.64K | 30.66K | 3.41K | 919.00 | 0.00 |
| EBITDA | -3.82M | -2.13M | -4.21M | -1.27M | -1.63M | 0.00 | -310.59K | -661.33K | -2.04M | -1.28M | -1.71M | -2.25M | -4.40M | -324.70K | -271.23K | -24.22K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -153.37% | -261.12% | -796.47% | -443.56% | -460.40% | -718.78% | -3,045.24% | -2,012.75% | 0.00% | 0.00% |
| Operating Income | -3.82M | -2.13M | -4.21M | -1.27M | -1.63M | -214.71K | -310.59K | -671.28K | -2.09M | -1.28M | -1.97M | -2.29M | -2.35M | -329.03K | -272.15K | -24.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -162.55% | -272.33% | -817.88% | -464.67% | -472.64% | -731.76% | -3,085.42% | -2,039.63% | 0.00% | 0.00% |
| Total Other Income/Expenses | -550.11K | -523.19K | -313.61K | -1.27M | -227.01K | -81.31K | -7.80K | -25.48K | -7.80K | -66.20K | 193.94K | -3.55K | -4.40K | -7.44K | -4.20K | 0.00 |
| Income Before Tax | -4.37M | -2.66M | -4.53M | -2.54M | -1.86M | -296.02K | -318.39K | -696.76K | -2.10M | -1.35M | -1.78M | -2.29M | -2.36M | -336.47K | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -166.63% | -282.67% | -820.93% | -488.69% | -426.16% | -732.90% | -3,091.18% | -2,085.73% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -193.37K | -182.69K | 1.21M | 227.01K | 400.00 | 7.80K | 25.48K | 7.80K | 66.20K | -193.94K | 3.55K | 4.40K | 7.44K | -919.00 | 24.32K |
| Net Income | -4.28M | -2.46M | -4.35M | -3.75M | -2.09M | -296.42K | -318.39K | -696.76K | -2.10M | -1.35M | -1.78M | -2.29M | -2.36M | -336.47K | -276.35K | -24.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -166.63% | -282.67% | -820.93% | -488.69% | -426.16% | -732.90% | -3,091.18% | -2,085.73% | 0.00% | 0.00% |
| EPS | -0.03 | -0.02 | -0.04 | -0.04 | -0.02 | 0.00 | -0.24 | -0.79 | -6.25 | -9.07 | -14.23 | -26.08 | -50.25 | -55.99 | -32.36 | -2.85 |
| EPS Diluted | -0.03 | -0.02 | -0.04 | -0.04 | -0.02 | 0.00 | -0.24 | -0.79 | -6.25 | -9.07 | -14.23 | -26.08 | -50.25 | -55.99 | -32.36 | -2.85 |
| Weighted Avg Shares Out | 134.22M | 115.14M | 106.25M | 93.97M | 85.60M | 85.10M | 1.32M | 883.50K | 336.07K | 148.43K | 125.02K | 87.94K | 46.93K | 6.01K | 8.54K | 8.54K |
| Weighted Avg Shares Out (Dil) | 134.22M | 115.14M | 106.25M | 93.97M | 85.60M | 85.10M | 1.32M | 883.50K | 336.07K | 148.43K | 125.02K | 87.94K | 46.93K | 6.01K | 8.54K | 8.54K |
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
Bioxytran's positive Phase 2 trial results featured in ‘Vaccines' peer-reviewed journal
Source: https://incomestatements.info
Category: Stock Reports